HomeVLA • EPA
Valneva SE
€2.13
Jan 14, 1:26:18 PM GMT+1 · EUR · EPA · Disclaimer
StockFR listed security
Previous close
€2.16
Day range
€2.11 - €2.19
Year range
€1.73 - €4.41
Market cap
345.87M EUR
Avg Volume
983.45K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
(EUR)Sep 2024Y/Y change
Revenue
45.82M20.36%
Operating expense
13.66M234.94%
Net income
-9.24M73.01%
Net profit margin
-20.1677.58%
Earnings per share
-0.1571.80%
EBITDA
-12.40M-16.52%
Effective tax rate
28.71%
Total assets
Total liabilities
(EUR)Sep 2024Y/Y change
Cash and short-term investments
156.34M-8.71%
Total assets
516.61M-0.75%
Total liabilities
299.14M-17.59%
Total equity
217.47M
Shares outstanding
140.53M
Price to book
1.39
Return on assets
-6.31%
Return on capital
-7.80%
Net change in cash
(EUR)Sep 2024Y/Y change
Net income
-9.24M73.01%
Cash from operations
-10.48M85.32%
Cash from investing
-15.38M-751.14%
Cash from financing
51.86M45.62%
Net change in cash
24.92M175.16%
Free cash flow
-41.46M41.47%
About
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
Founded
2013
Employees
700
Search
Clear search
Close search
Google apps
Main menu